abbv-368
mAbexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 3, 2017 (NCT03071757)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
TNFSF4 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- abbv-368
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04196283 | Phase 1 | Dec 14, 2019 | AbbVie, Aceragen, Inc/ |
| NCT03893955 | Phase 1 | May 21, 2019 | AbbVie |
| NCT03818542 | Phase 1 | Mar 8, 2019 | AbbVie |
| NCT03071757 | Phase 1 | Apr 3, 2017 | AbbVie |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AbbVie | For profit | 4 | 4 | 1 | 2017 |
| Aceragen, Inc/ | For profit | 1 | 0 | 1 | 2019 |
2 organizations
Page 1 / 1